Castleark Management’s BridgeBio Pharma BBIO Stock Holding History

Castleark Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.07M	Sell	81,737 -32,280	-28%	-$2.34M	0.2%	127
2025 Q4	$8.72M	Sell	114,017 -9,690	-8%	-$636K	0.26%	82
2025 Q3	$6.43M	Buy	123,707 +45,867	+59%	+$2.24M	0.18%	127
2025 Q2	$3.36M	Sell	77,840 -29,140	-27%	-$1.06M	0.1%	151
2025 Q1	$3.7M	Buy	+106,980	New	+$3.61M	0.13%	149
2022 Q4	–	Sell	-90,470	Closed	-$899K	–	287
2022 Q3	$899K	Buy	+90,470	New	+$940K	0.05%	195
2021 Q3	–	Sell	-46,457	Closed	-$2.83M	–	334
2021 Q2	$2.83M	Sell	46,457 -60,053	-56%	-$3.43M	0.1%	174
2021 Q1	$6.56M	Buy	+106,510	New	+$6.97M	0.24%	119

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleark Management's BBIO Position: Q1 2026 in Review

Castleark Management reduced its BridgeBio Pharma (BBIO) stake by 28% in Q1 2026, selling an estimated $2.34M and leaving 81,737 shares worth $6.07M. The position accounts for 0.2% of the portfolio, ranked #127.

Castleark Management first reported a position in BBIO in Q1 2021 and has held it in 8 quarters since. The position peaked at $8.72M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Castleark Management held 81,737 shares of BridgeBio Pharma worth $6.07M as of Q1 2026.
Castleark Management sold 32,280 BridgeBio Pharma shares in Q1 2026, an estimated $2.34M.
BridgeBio Pharma made up 0.2% of Castleark Management's portfolio in Q1 2026, its #127 holding.
Castleark Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 8 quarters since.
Castleark Management's BridgeBio Pharma position peaked at $8.72M in Q4 2025.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.